Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of E/C/F/TAF versus E/C/F/TDF in treatment-naive adults with HIV-1
2012-004458-27Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide, tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1, sponsored by Gilead Sciences. Started Feb 2013; status: completed.
02
Drugs
elvitegravircobicistatemtricitabinetenofovir alafenamidetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2012-004458-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004458-27.